The International Vaccine Institute in South Korea and the Saudi Ministry of Health required strategic and facilitation support to advance a collaborative approach to MERS-CoV vaccine development.
A top-5 global biopharmaceutical company wanted to identify promising oncology drug candidates that it could in-license or acquire to bolster its oncology franchise revenues over the near term.
Recognizing the dynamic nature of the psychiatry therapeutic arena, a top-5 pharmaceutical company required support in characterizing and prioritizing the stakeholder environment to inform how Medical Affairs could work with other functions to optimize patient care.
Shift Health was engaged by Ryerson University to develop a briefing note to engage investors for an institute focused on advancing the R&D of biomedical engineering technologies.
Shift Health was engaged to conduct an independent operational review of an infectious disease research institute funded and operated by the US and Thai governments.
To inform future knowledge transfer efforts, the Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA) needed to assess activities delivered under the Growing Forward 2 program.
A global pharmaceutical company wanted to identify diagnostic technologies that would support the clinical development and commercial performance of agents targeting two infectious diseases and represent potential partnership opportunities.
Shift Health was engaged by a newly formed government-funded agency to develop a foreign direct investment (FDI) attraction strategy for the Toronto Region’s healthcare and life sciences cluster.
A leading pharmaceutical company required support in identifying and planning for risks and scenarios that could arise during a multinational Phase 3 vaccine clinical trial.